Gilead Sciences (GILD) Work In Process (2009 - 2015)
Gilead Sciences (GILD) reported Work In Process of $542.0 million for Q4 2015, up 8.4% on a YoY basis from $500.0 million in Q4 2014, and up 8.4% quarter-over-quarter from $500.0 million in Q4 2014.
Gilead Sciences (GILD) Work In Process (2009 - 2015) Analysis & Trends
Gilead Sciences has reported Work In Process for 7 years, with the latest figure at $542.0 million in Q4 2015.
- For the quarter ending Q4 2015, Work In Process rose 8.4% year-over-year to $542.0 million; the trailing twelve-month figure through Dec 2015 stood at $542.0 million (up 8.4% YoY), and the FY2015 full-year result was $542.0 million, up 8.4% from the prior year.
- Work In Process for Q4 2015 stood at $542.0 million, up from $500.0 million in the prior quarter.
- The five-year high for Work In Process was $563.9 million in Q2 2014, with the low at $175.5 million in Q3 2011.
- Historically, Work In Process has averaged $398.7 million across 5 years, with a median of $412.9 million in 2013.
- Annual changes were most pronounced in 2011 — Work In Process plunged 55.28% — and 2014, when it gained 21.08%.
- Gilead Sciences' Work In Process stood at $466.5 million in 2011, then declined by 23.15% to $358.5 million in 2012, then climbed by 15.18% to $412.9 million in 2013, then grew by 21.08% to $500.0 million in 2014, then grew by 8.4% to $542.0 million in 2015.
- The last three Work In Process figures came in at $542.0 million (Q4 2015), $500.0 million (Q4 2014), and $563.9 million (Q2 2014), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 92,316,836.42 Bn | 92,316,831.46 Bn | 7.76 Bn |
| 2 | Eli Lilly | 983.57 Bn | 978.29 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 553.56 Bn | 531.50 Bn | 15.96 Bn |
| 4 | AbbVie | 383.35 Bn | 374.00 Bn | 10.78 Bn |
| 5 | Merck | 281.71 Bn | 276.06 Bn | 12.09 Bn |
| 6 | Amgen | 182.20 Bn | 170.16 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 153.71 Bn | 145.98 Bn | 5.52 Bn |
| 8 | Pfizer | 143.75 Bn | 130.98 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 109.71 Bn | 99.25 Bn | 8.07 Bn |
| 10 | Novartis Ag | 108.28 Bn | 107.60 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2015 | 542.00 Mn |
| Dec 31, 2014 | 500.00 Mn |
| Jun 30, 2014 | 563.88 Mn |
| Dec 31, 2013 | 412.95 Mn |
| Dec 31, 2012 | 358.53 Mn |
| Dec 31, 2011 | 466.50 Mn |
| Sep 30, 2011 | 175.55 Mn |
| Jun 30, 2011 | 271.64 Mn |
| Mar 31, 2011 | 296.87 Mn |
| Dec 31, 2010 | 454.65 Mn |
| Sep 30, 2010 | 392.54 Mn |
| Dec 31, 2009 | 392.04 Mn |